Literature DB >> 27503932

Adaptive NK Cells with Low TIGIT Expression Are Inherently Resistant to Myeloid-Derived Suppressor Cells.

Dhifaf Sarhan1, Frank Cichocki1, Bin Zhang2, Ashley Yingst3, Stephen R Spellman4, Sarah Cooley1, Michael R Verneris3, Bruce R Blazar3, Jeffrey S Miller5.   

Abstract

Human cytomegalovirus (CMV)-induced adaptive natural killer (NK) cells display distinct phenotypic and functional characteristics, including properties of immune memory. We hypothesized that these cells may be more resistant to suppression mediated by immunoregulatory cell subsets, making them attractive for use in cancer therapy. Here we report that relative to conventional NK cells, adaptive NK cells express lower levels of the inhibitory receptor T-cell Ig and ITIM domain (TIGIT), which results in resistance to immune suppression mediated by myeloid-derived suppressor cells (MDSC), as derived from cytokine induction in normal blood or patients with myelodysplastic syndrome. In contrast, conventional NK cells were potently suppressed by MDSCs, an effect abrogated completely by TIGIT blockade. Mechanistically, TIGIT signaling in NK cells after MDSC coculture led to a decrease in the phosphorylation of ZAP70/Syk and ERK1/2. These effects were reversed by blocking TIGIT on NK cells or by inhibiting production of reactive oxygen species (ROS) by MDSCs, the latter of which upregulated the TIGIT ligand CD155 on MDSCs. Accordingly, the blunted cytotoxicity of NK cells cocultured with MDSCs against tumor cells could be reversed by blocking TIGIT or ROS production. Overall, our results show how adaptive NK cells arising in response to CMV infection can escape MDSC-mediated suppression, and defined TIGIT antagonists as a novel type of checkpoint inhibitor to enhance NK-cell-mediated responses against cancer and infection. Cancer Res; 76(19); 5696-706. ©2016 AACR. ©2016 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27503932      PMCID: PMC5050142          DOI: 10.1158/0008-5472.CAN-16-0839

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  47 in total

1.  Characterization of cytokine-induced myeloid-derived suppressor cells from normal human peripheral blood mononuclear cells.

Authors:  Melissa G Lechner; Daniel J Liebertz; Alan L Epstein
Journal:  J Immunol       Date:  2010-07-19       Impact factor: 5.422

2.  CTLA-4⁺ Regulatory T Cells Increased in Cetuximab-Treated Head and Neck Cancer Patients Suppress NK Cell Cytotoxicity and Correlate with Poor Prognosis.

Authors:  Hyun-Bae Jie; Patrick J Schuler; Steve C Lee; Raghvendra M Srivastava; Athanassios Argiris; Soldano Ferrone; Theresa L Whiteside; Robert L Ferris
Journal:  Cancer Res       Date:  2015-04-01       Impact factor: 12.701

3.  PDL1 expression is an independent prognostic factor in localized GIST.

Authors:  François Bertucci; Pascal Finetti; Emilie Mamessier; Maria Abbondanza Pantaleo; Annalisa Astolfi; Jerzy Ostrowski; Daniel Birnbaum
Journal:  Oncoimmunology       Date:  2015-02-03       Impact factor: 8.110

4.  B7-H6 expression correlates with cancer progression and patient's survival in human ovarian cancer.

Authors:  Yi Zhou; Yun Xu; Lujun Chen; Bin Xu; Changping Wu; Jingting Jiang
Journal:  Int J Clin Exp Pathol       Date:  2015-08-01

5.  Clearance of acute myeloid leukemia by haploidentical natural killer cells is improved using IL-2 diphtheria toxin fusion protein.

Authors:  Veronika Bachanova; Sarah Cooley; Todd E Defor; Michael R Verneris; Bin Zhang; David H McKenna; Julie Curtsinger; Angela Panoskaltsis-Mortari; Dixie Lewis; Keli Hippen; Philip McGlave; Daniel J Weisdorf; Bruce R Blazar; Jeffrey S Miller
Journal:  Blood       Date:  2014-04-09       Impact factor: 22.113

Review 6.  Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected.

Authors:  Douglas Marvel; Dmitry I Gabrilovich
Journal:  J Clin Invest       Date:  2015-07-13       Impact factor: 14.808

7.  Melanoma Cells Control Antimelanoma CTL Responses via Interaction between TIGIT and CD155 in the Effector Phase.

Authors:  Takashi Inozume; Tomonori Yaguchi; Junpei Furuta; Kazutoshi Harada; Yutaka Kawakami; Shinji Shimada
Journal:  J Invest Dermatol       Date:  2016-01       Impact factor: 8.551

8.  Myeloid derived suppressor cells inhibit natural killer cells in patients with hepatocellular carcinoma via the NKp30 receptor.

Authors:  Bastian Hoechst; Torsten Voigtlaender; Lars Ormandy; Jaba Gamrekelashvili; Fei Zhao; Heiner Wedemeyer; Frank Lehner; Michael P Manns; Tim F Greten; Firouzeh Korangy
Journal:  Hepatology       Date:  2009-09       Impact factor: 17.425

9.  NK cells and CD8+ T cells cooperate to improve therapeutic responses in melanoma treated with interleukin-2 (IL-2) and CTLA-4 blockade.

Authors:  Frederick J Kohlhapp; Joseph R Broucek; Tasha Hughes; Erica J Huelsmann; Jevgenijs Lusciks; Janet P Zayas; Hubert Dolubizno; Vidyaratna A Fleetwood; Alisa Grin; Graham E Hill; Joseph L Poshepny; Arman Nabatiyan; Carl E Ruby; Joshua D Snook; Jai S Rudra; Jason M Schenkel; David Masopust; Andrew Zloza; Howard L Kaufman
Journal:  J Immunother Cancer       Date:  2015-05-19       Impact factor: 13.751

Review 10.  Controlling natural killer cell responses: integration of signals for activation and inhibition.

Authors:  Eric O Long; Hun Sik Kim; Dongfang Liu; Mary E Peterson; Sumati Rajagopalan
Journal:  Annu Rev Immunol       Date:  2013       Impact factor: 28.527

View more
  65 in total

1.  161533 TriKE stimulates NK-cell function to overcome myeloid-derived suppressor cells in MDS.

Authors:  Dhifaf Sarhan; Ludwig Brandt; Martin Felices; Karolin Guldevall; Todd Lenvik; Peter Hinderlie; Julie Curtsinger; Erica Warlick; Stephen R Spellman; Bruce R Blazar; Daniel J Weisdorf; Sarah Cooley; Daniel A Vallera; Björn Önfelt; Jeffrey S Miller
Journal:  Blood Adv       Date:  2018-06-26

2.  Nitric Oxide Production by Myeloid-Derived Suppressor Cells Plays a Role in Impairing Fc Receptor-Mediated Natural Killer Cell Function.

Authors:  Andrew Stiff; Prashant Trikha; Bethany Mundy-Bosse; Elizabeth McMichael; Thomas A Mace; Brooke Benner; Kari Kendra; Amanda Campbell; Shalini Gautam; David Abood; Ian Landi; Vincent Hsu; Megan Duggan; Robert Wesolowski; Matthew Old; John Harrison Howard; Lianbo Yu; Nancy Stasik; Thomas Olencki; Natarajan Muthusamy; Susheela Tridandapani; John C Byrd; Michael Caligiuri; William E Carson
Journal:  Clin Cancer Res       Date:  2018-01-23       Impact factor: 12.531

Review 3.  Targeting novel inhibitory receptors in cancer immunotherapy.

Authors:  Quan-Quan Ding; Joe-Marc Chauvin; Hassane M Zarour
Journal:  Semin Immunol       Date:  2020-12-04       Impact factor: 11.130

4.  A Phase 1 Trial of CNDO-109-Activated Natural Killer Cells in Patients with High-Risk Acute Myeloid Leukemia.

Authors:  Todd A Fehniger; Jeffrey S Miller; Robert K Stuart; Sarah Cooley; Amandeep Salhotra; Julie Curtsinger; Peter Westervelt; John F DiPersio; Timothy M Hillman; Nova Silver; Michael Szarek; Leonid Gorelik; Mark W Lowdell; Eric Rowinsky
Journal:  Biol Blood Marrow Transplant       Date:  2018-03-27       Impact factor: 5.742

5.  Myeloid-derived suppressor cell-dependent inhibition of B cell responses in non-small cell lung cancer.

Authors:  Rui Li; Steven M Dubinett
Journal:  Transl Lung Cancer Res       Date:  2019-12

Review 6.  Harnessing NK Cell Memory for Cancer Immunotherapy.

Authors:  Todd A Fehniger; Megan A Cooper
Journal:  Trends Immunol       Date:  2016-10-21       Impact factor: 16.687

7.  Adaptive NK Cells Resist Regulatory T-cell Suppression Driven by IL37.

Authors:  Dhifaf Sarhan; Keli L Hippen; Amanda Lemire; Skyler Hying; Xianghua Luo; Todd Lenvik; Julie Curtsinger; Zachary Davis; Bin Zhang; Sarah Cooley; Frank Cichocki; Bruce R Blazar; Jeffrey S Miller
Journal:  Cancer Immunol Res       Date:  2018-05-21       Impact factor: 11.151

8.  Haploidentical natural killer cells induce remissions in non-Hodgkin lymphoma patients with low levels of immune-suppressor cells.

Authors:  Veronika Bachanova; Dhifaf Sarhan; Todd E DeFor; Sarah Cooley; Angela Panoskaltsis-Mortari; Bruce R Blazar; Julie M Curtsinger; Linda Burns; Daniel J Weisdorf; Jeffrey S Miller
Journal:  Cancer Immunol Immunother       Date:  2017-12-07       Impact factor: 6.968

Review 9.  Tim-3, Lag-3, and TIGIT.

Authors:  Nicole Joller; Vijay K Kuchroo
Journal:  Curr Top Microbiol Immunol       Date:  2017       Impact factor: 4.291

Review 10.  Prognostic role of pretreatment circulating MDSCs in patients with solid malignancies: A meta-analysis of 40 studies.

Authors:  Peng-Fei Wang; Si-Ying Song; Ting-Jian Wang; Wen-Jun Ji; Shou-Wei Li; Ning Liu; Chang-Xiang Yan
Journal:  Oncoimmunology       Date:  2018-07-30       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.